<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02973529</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-215-14</org_study_id>
    <nct_id>NCT02973529</nct_id>
  </id_info>
  <brief_title>The Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study</brief_title>
  <acronym>BIFSORB</acronym>
  <official_title>Bioresorbable Vascular Stents for Treatment of Coronary Bifurcation Lesions Assessed by Optical Coherence Tomography - The BIFSORB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease is often treated by implantation of permanent metallic&#xD;
      stents.Coronary stents are required in the early healing phase after balloon dilatation but&#xD;
      constitute a lifelong foreign body. New bioresorbable stents have been developed and are&#xD;
      believed to improve long-term safety. The purpose of this study is to compare the safety and&#xD;
      vessel healing after treatment of simple bifurcation lesions with the CE-marked bioresorbable&#xD;
      stents Absorb and Desolve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BIFSORB is a prospective, randomized multicenter trial comparing 6-month healing outcome&#xD;
      after treatment of simple coronary bifurcation lesions by Absorb or Desolve BRS. for&#xD;
      treatment of coronary bifurcation lesions.&#xD;
&#xD;
      BRS are promising in treatment of coronary artery disease. The concept of bifurcation&#xD;
      treatment using BRS is particular appealing as struts covering the side branch ostium may&#xD;
      resorb over time.&#xD;
&#xD;
      The aim of this study is to compare the 6 months safety and vessel healing after treatment of&#xD;
      coronary bifurcation lesions by the Desolve or Absorb BRS.&#xD;
&#xD;
      Hypothesis: Treatment of coronary bifurcation lesions using Absorb and Desolve bioresorbable&#xD;
      stents is safe. Treatment of coronary bifurcation lesions by Desolve BRS is associated with a&#xD;
      lower index of adverse vessel wall features (main vessel area stenosis, acquired&#xD;
      malapposition, evaginations, late recoil, single end attached protruding struts, side branch&#xD;
      ostial area stenosis) at 6 months compared to treatment with Absorb BRS.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Prospective, open label, single blind, randomized, feasibility and safety pilot study with&#xD;
      inclusion of 120 patients. Randomization 1:1 to Absorb or Desolve. Planned 6- and 24-month&#xD;
      follow-up by OCT and follow-up for clinical endpoints until 10 years.&#xD;
&#xD;
      Eligible patients with a bifurcation lesion are treated by the provisional technique with&#xD;
      mandatory jailing of the side branch and provisional opening of side branch ostium by the&#xD;
      mini-kiss technique in case of severe pinching or TIMI-flow less than III. Proximal&#xD;
      post-dilatation is mandatory. No dilatation beyond the expansion limits of the BRS.&#xD;
&#xD;
      The patients are assessed by optical coherence tomography (OCT) before, during and after&#xD;
      implantation of the Absorb or Desolve BRS at baseline procedure and again at 6- and 24-month&#xD;
      follow-up, or before if they are readmitted with a possible target lesion failure.&#xD;
&#xD;
      The operator is not blinded to pre-PCI OCT images that may be used for sizing and positioning&#xD;
      of the scaffolds. Procedural OCT may be used to optimize scaffold implantation before&#xD;
      performing final OCT.&#xD;
&#xD;
      Results are reported as clinical safety at 6 months (myocardial infarction,&#xD;
      revascularization, death) and stent healing index by OCT including malapposition, stent&#xD;
      coverage, side branch ostial area late loss, fracture and evaginations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Clinical safety measured as: major procedural myocardial infarction, non-procedural target vessel myocardial infarction, target lesion failure, cardiac death.</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical safety measured as: major procedural myocardial infarction, non-procedural target vessel myocardial infarction, target lesion failure, cardiac death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of adverse vessel wall features</measure>
    <time_frame>6 months</time_frame>
    <description>Side branch ostial area late loss, strut fracture, uncovered non-side branch apposed stent struts, uncovered stent struts in front of side branch, uncovered stent struts on acquired or persistent malapposed struts, persistent malapposition, max neointimal thickness/area stenosis, cumulated extra stent lumen gain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: acute malapposition</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: acquired malapposition</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: persistent malapposition</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Coverage of jailing struts</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Extra stent lumen (including evaginations)</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Late stent recoil</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: stent fracture</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Single end attached protruding (floating) struts or neointimal tissue resembling struts</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Ostial strut loss</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Mean neointimal thickness</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Stent strut coverage</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Minimal luminal area in segmental analysis</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Minimal stent area in segmental analysis</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Minimum scaffold expansion area %</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Segmental area stenosis</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Healing above calcified plaque</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Healing above lipid plaque</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Acute thrombus on struts</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Late thrombus on struts</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Acute expansion</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured in segments with; 1) calcified plaque, 2) lipid plaque, 3) area after predilatation &lt; 30% of reference area, 4) stenosed segments (&gt;50% area stenosis) with no dissections after predilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint:Late recoil</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>Measured in segments with; 1) calcified plaque, 2) lipid plaque, 3) area after predilatation &lt; 30% of reference area, 4) stenosed segments (&gt;50% area stenosis) with no dissections after predilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial side branch area stenosis</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial side branch acute gain after main vessel stenting</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial side branch late loss</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial distal main vessel area stenosis</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial distal main vessel acute gain after main vessel stenting</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial distal main vessel late loss</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Proximal main vessel area stenosis</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Proximal main vessel acute gain after main vessel stenting</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Proximal main vessel late loss</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Minimal luminal area of all segments</measure>
    <time_frame>Baseline, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural endpoints: Procedure time</measure>
    <time_frame>Baseline</time_frame>
    <description>From sheath insertion to closure device excluding treatment of other vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural endpoints: Contrast use</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural endpoints: Fluoroscopy time</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical endpoints: Myocardial infarction</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoints: Target lesion failure</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoints: Target lesion revascularization</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoints: Stent thrombosis</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoints: Cardiac death</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoints: Non-Cardiac death</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Absorb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization to implantation of Absorb BVS in bifurcation lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desolve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization to implantation of Desolve BRS in bifurcation lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb</intervention_name>
    <description>Randomization to implantation of Absorb BVS in bifurcation lesion</description>
    <arm_group_label>Absorb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Desolve</intervention_name>
    <description>Randomization to implantation of Desolve BRS in bifurcation lesion</description>
    <arm_group_label>Desolve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable angina pectoris&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Stabilized non-ST elevation myocardial infarction&#xD;
&#xD;
          -  Silent angina&#xD;
&#xD;
          -  De novo coronary bifurcation lesions at LAD/diagonal, CX/obtuse marginal,&#xD;
             RCA-PDA/posterolateral branch&#xD;
&#xD;
          -  All Medina classes except Medina x.x.1&#xD;
&#xD;
          -  Diameter of side branch ≥ 2.5 mm&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ST-elevation infarction within 48 hours&#xD;
&#xD;
          -  Expected survival &lt; 1 year&#xD;
&#xD;
          -  Severe heart failure (NYHA≥III)&#xD;
&#xD;
          -  S-creatinine &gt; 120 µmol/L&#xD;
&#xD;
          -  Allergy to contrast media, aspirin, clopidogrel, ticagrelor, ticlopidine, everolimus&#xD;
             or novolimus&#xD;
&#xD;
          -  Unable to cover main vessel lesion with one scaffold&#xD;
&#xD;
          -  Severe tortuosity&#xD;
&#xD;
          -  Severe calcification&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evald H Christiansen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvian Heart Center</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Latvia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Evald Hoej Christiansen</investigator_full_name>
    <investigator_title>Principal investigator (MD, PhD)</investigator_title>
  </responsible_party>
  <keyword>Percutaneous intervention (PCI)</keyword>
  <keyword>Optical coherence tomography (OCT)</keyword>
  <keyword>Bifurcation lesion</keyword>
  <keyword>Bioresorbable stents (BRS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

